CIBMTR®
CENTER FOR INTERNATIONAL BLOOD & MARROW TRANSPLANT RESEARCH

Pre-Transplant Essential Data

OMB No: 0915-0310

Expiration Date: 10/31/2022

CIBMTR Use Only

Sequence Number:

Date Received:

Center Identification

CIBMTR Center Number: ___ ___ ___ ___ ___

EBMT Code (CIC): ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Recipient Identification

CIBMTR Research ID (CRID): ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Event date: __ __ __ __ / __ __ / __ __
_____YYYYMM
_____DD

CIBMTR Center Number: ___ ___ ___ ___ ___ CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

Recipient Information

1. Date of birth: ___ ___ ___ ___ — ___ ___ — ___ ___
   YYYY MM DD

2. Sex
   - ☐ Male
   - ☐ Female

3. Ethnicity
   - ☐ Hispanic or Latino
   - ☐ Not Hispanic or Latino
   - ☐ Not applicable *(not a resident of the USA)*
   - ☐ Unknown

4. Race *(check all that apply)*
   - ☐ White – ***Go to question 5.***
   - ☐ Black or African American– ***Go to question 5.***
   - ☐ Asian– ***Go to question 5.***
   - ☐ American Indian or Alaska Native– ***Go to question 5.***
   - ☐ Native Hawaiian or Other Pacific Islander– ***Go to question 5.***
   - ☐ Not reported – ***Go to question 6.***
   - ☐ Unknown– ***Go to question 6.***

5. Race detail *(check all that apply)*
   - ☐ Eastern European
   - ☐ Mediterranean
   - ☐ Middle Eastern
   - ☐ North Coast of Africa
   - ☐ North American
   - ☐ Northern European
   - ☐ Western European
   - ☐ White Caribbean

OMB No: 0915-0310 Expiration Date: 10/31/2022

- ☐ White South or Central American
- ☐ Other White
- ☐ African
- ☐ African American
- ☐ Black Caribbean
- ☐ Black South or Central American
- ☐ Other Black
- ☐ Alaskan Native or Aleut
- ☐ North American Indian
- ☐ American Indian, South or Central America
- ☐ Caribbean Indian
- ☐ South Asian
- ☐ Filipino (Pilipino)
- ☐ Japanese
- ☐ Korean
- ☐ Chinese
- ☐ Vietnamese
- ☐ Other Southeast Asian
- ☐ Guamanian
- ☐ Hawaiian
- ☐ Samoan
- ☐ Other Pacific Islander
- ☐ Unknown

6. Country of primary residence

7. State of residence of recipient *(for residents of Brazil)* _____ - ***Go to question 10.***

8. Province or territory of residence of recipient *(for residents of Canada)* _____- ***Go to question 10.***

9. State of residence of recipient *(for residents of USA)* _____

10. NMDP Recipient ID (RID): __ __ __ __ __ __ __

11. Zip or postal code for place of recipient's residence *(USA recipients only)*: ___ ___ ___ ___ ___ - ___ ___ ___ ___

(last 4 digits optional)

12. Specify blood type *(of recipient)* **(For allogeneic HCTs only)**

- ☐ A
- ☐ B
- ☐ AB
- ☐ O

13. Specify Rh factor *(of recipient)* **(For allogeneic HCTs only)**

- ☐ Positive
- ☐ Negative

14. Has the recipient signed an IRB / ethics committee (or similar body) approved consent form for submitting research data to the NMDP / CIBMTR?

- ☐ Yes *(recipient consented)* – ***Go to question 15.***
- ☐ No *(recipient declined)* – ***Go to question 17.***
- ☐ Not approached – ***Go to question 17.***

15. Did the recipient give permission to be directly contacted by CIBMTR for future research?

- ☐ Yes *(recipient provided permission)* – ***Go to question 16.***
- ☐ No *(recipient declined)* – ***Go to question 17.***

16. Date form was signed: ___ ___ ___ ___ — ___ ___ — ___ ___

YYYY MM DD

17. Has the recipient signed an IRB / ethics committee (or similar body) approved consent form to donate research blood samples to the NMDP / CIBMTR?

- ☐ Yes *(recipient consented)* – ***Go to question 18.***
- ☐ No *(recipient declined)* - ***Go to question 21.***
- ☐ Not approached - ***Go to question 21.***
- ☐ Not applicable *(center not participating)* - ***Go to question 21.***

18. Date form was signed: ___ ___ ___ ___ — ___ ___ — ___ ___

YYYY MM DD

19. Did the recipient submit a research sample to the NMDP/CIBMTR repository? **(Related donors only)**

- ☐ Yes – ***Go to question 20.***
- ☐ No – ***Go to question 21.***

20. Research sample recipient ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

OMB No: 0915-0310 Expiration Date: 10/31/2022

21. Is the recipient participating in a clinical trial? *(clinical trial sponsors that use CIBMTR forms to capture outcomes data)*

☐ Yes - ***Go to question 22.***

☐ No – ***Go to question 26.***

22. Study Sponsor

- ☐ BMT CTN ***– Go to question 24.***
- ☐ RCI BMT ***– Go to question 24.***
- ☐ PIDTC ***– Go to question 24.***
- ☐ USIDNET ***– Go to question 25.***
- ☐ COG ***– Go to question 25.***
- ☐ Other sponsor ***– Go to question 23.***

23. Specify other sponsor: _____ ***- Go to question 25.***

24. Study ID Number: _____

25. Subject ID: _____

Copy questions 22.-25. to report participation in more than one study.

Hematopoietic Cellular Transplant (HCT) and Cellular Therapy

26. Is a subsequent HCT planned as part of the overall treatment protocol? *(not as a reaction to post-HCT disease assessment)* **(For autologous HCTs only)**

- ☐ Yes – ***Go to question 27.***
- ☐ No – ***Go to question 28.***

27. Specify subsequent HCT planned

- ☐ Autologous
- ☐ Allogeneic

28. Has the recipient ever had a prior HCT?

☐ Yes – ***Go to question 29.***

☐ No – ***Go to question 40.***

29. Specify the number of prior HCTs: ___ ___

30. Were all prior HCTs reported to the CIBMTR?

☐ Yes – ***Go to question 35.***

☐ No – ***Go to question 31.***

☐ Unknown – ***Go to question 31.***

Copy and complete questions 31.- 34. to report all prior HCTs that have not yet been reported to the CIBMTR

31. Date of the prior HCT: ___ ___ ___ ___ — ___ ___ — ___ ___ ☐ date estimated

YYYY MM DD

32. Was the prior HCT performed at a different institution?

☐ Yes – ***Go to question 33.***

☐ No – ***Go to question 34.***

Specify the institution that performed the last HCT

33. Name: _____

City: _____

State: _____

Country: _____

34. What was the HPC source for the prior HCT? (check all that apply)

☐ Autologous

☐ Allogeneic, unrelated

☐ Allogeneic, related

35. Reason for current HCT

☐ Graft failure / insufficient hematopoietic recovery – ***Go to question 36.***

☐ Persistent primary disease– ***Go to question 40.***

☐ Recurrent primary disease– ***Go to question 37.***

☐ Planned subsequent HCT, per protocol– ***Go to question 40.***

☐ New malignancy *(including PTLD and EBV lymphoma)* – ***Go to question 38.***

☐ Insufficient chimerism– ***Go to question 40.***

☐ Other– ***Go to question 39.***

OMB No: 0915-0310 Expiration Date: 10/31/2022

36. Date of graft failure / rejection: ___ ___ ___ ___ — ___ ___ — ___ ___ – ***Go to question 40.***

YYYY MM DD

37. Date of relapse: ___ ___ ___ ___ — ___ ___ — ___ ___ – ***Go to question 40.***

YYYY MM DD

38. Date of secondary malignancy: ___ ___ ___ ___ — ___ ___ — ___ ___ – ***Go to question 40.***

YYYY MM DD

39. Specify other reason: _____ - ***Go to question 40.***

40. Has the recipient ever had a prior cellular therapy? *(do not include DLIs)*

☐ Yes – ***Go to question 41.***

☐ No – ***Go to question 46.***

☐☐Unknown– ***Go to question 46.***

41. Were all prior cellular therapies reported to the CIBMTR?

☐ Yes – ***Go to question 46.***

☐ No – ***Go to question 42.***

☐ Unknown– ***Go to question 46.***

Copy and complete questions 42.-45. to report all prior cellular therapies that have not yet been reported to the CIBMTR

42. Date of the prior cellular therapy: __ __ __ __ -- __ __ -- __ __

YYYY MM DD

43. Was the cellular therapy performed at a different institution?

☐ Yes – ***Go to question 44.***

☐ No – ***Go to question 45.***

44. Name:

_____

City:

State:

Country:

45. Specify the source(s) for the prior cellular therapy *(check all that apply)*

- ☐ Autologous
- ☐ Allogeneic, unrelated
- ☐ Allogeneic, related

Donor Information

46. Multiple donors?

- ☐ Yes – ***Go to question 47.***
- ☐ No - ***Go to question 48.***

47. Specify number of donors: ___ ___

To report more than one donor, copy questions 48.-83. and complete for each donor.

48. Specify donor

- ☐ Autologous
- ☐ Allogeneic, related
- ☐ Allogeneic, unrelated

49. Specify product type *(check all that apply)*

- ☐ Bone marrow
- ☐ PBSC
- ☐ Single cord blood unit
- ☐ Other product– ***Go to question 50.***

50. Specify other product: _____

51. Is the product genetically modified?

- ☐ Yes
- ☐ No

If autologous, go to question 80..

If allogeneic related, go to question 52..

If allogeneic unrelated, go to question 56..

52. Specify the related donor type

- ☐ Syngeneic *(monozygotic twin)* – ***Go to question 57.***

- ☐ HLA-identical sibling *(may include non-monozygotic twin)* **– *Go to question 57.***
- ☐ HLA-matched other relative *(does NOT include a haplo-identical donor)* - ***Go to question*** 53.
- ☐ HLA-mismatched relative– ***Go to question 53.***

53. Specify the biological relationship of the donor to the recipient

- ☐ Mother
- ☐ Father
- ☐ Child
- ☐ Sibling
- ☐ Fraternal twin
- ☐ Maternal aunt
- ☐ Maternal uncle
- ☐ Maternal cousin
- ☐ Paternal aunt
- ☐ Paternal uncle
- ☐ Paternal cousin
- ☐ Grandparent
- ☐ Grandchild
- ☐ Other biological relative – ***Go to question 54.***

54. Specify other biological relative: _____– ***Go to question 55.***

55. Degree of mismatch *(related donors only)*

- ☐ HLA-mismatched 1 allele– ***Go to question 57.***
- ☐ HLA-mismatched ≥2 alleles *(does include haplo-identical donor)* – ***Go to question 57.***

56. Specify unrelated donor type

- ☐ HLA matched unrelated
- ☐ HLA mismatched unrelated

57. Did NMDP / Be the Match facilitate the procurement, collection, or transportation of the product?

- ☐ Yes
- ☐ No

58. Was this donor used for any prior HCTs? *(for this recipient)*

- ☐ Yes

☐ No

59. NMDP cord blood unit ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ – ***Go to question 63.***

60. NMDP donor ID: ___ ___ ___ ___ — ___ ___ ___ ___ — ___ ***Go to question 63.***

61. Non-NMDP unrelated donor ID: *(not applicable for related donors)*

___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ - ***Go to question 63.***

62. Non-NMDP cord blood unit ID: *(include related and autologous CBUs)*

___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ - ***Go to question 63.***

63. Global Registration Identifier for Donors (GRID): __ *(optional)*

NMDP cord blood unit, go to question 75.

NMDP donor, go to question 75.

Non-NMDP unrelated donor, go to question 66.

Non-NMDP cord blood unit, go to question 64.

64. Is the CBU ID also the ISBT DIN number?

☐ Yes – ***Go to question 66.***

☐ No – ***Go to question 65.***

☐ Unknown– ***Go to question 66.***

65. Specify the ISBT DIN number: _____

66. Registry or UCB Bank ID: ___ ___ ___ ___ - ***If 'Other registry' go to 67., otherwise go to question 68.***

67. Specify other Registry or UCB Bank: _____ - ***Go to question 68.***

68. Date of birth *(donor / infant)*

☐ Known – ***Go to question 69.***

☐ Unknown – ***Go to question 70.***

69. Date of birth: *(donor / infant)* ___ ___ ___ ___ — ___ ___ — ___ ___ - ***Go to question 72.***

YYYY MM DD

70. Age *(donor / infant)*

☐ Known – ***Go to question 71.***

☐ Unknown – ***Go to question 72.***

71. Age: *(donor / infant)* ___ ___ ☐ Months *(use only if less than 1 year old)*

☐ Years

72. Sex *(donor / infant)*

☐ Male

☐ Female

73. Specify blood type *(donor)* **(non-NMDP allogeneic donors only)**

☐ A

☐ B

☐ AB

☐ O

74. Specify Rh factor *(donor)* **(non-NMDP allogeneic donors only)**

☐ Positive

☐ Negative

75. Donor CMV-antibodies *(IgG or Total)* **(Allogeneic HCTs only)**

☐ Reactive

☐ Non-reactive

☐ Indeterminate

☐ Not done

☐ Not applicable *(cord blood unit)*

76. Has the donor signed an IRB / ethics committee (or similar body) approved consent form to donate research blood samples to the NMDP / CIBMTR? **(Related donors only)**

☐ Yes *(donor consented)* – ***Go to question 77.***

☐ No *(donor declined)* - ***Go to question 80.***

☐ Not approached - ***Go to question 80.***

☐ Not applicable *(center not participating)* - ***Go to question 80.***

OMB No: 0915-0310 Expiration Date: 10/31/2022

77. Date form was signed: ___ ___ ___ ___ — ___ ___ — ___ ___
YYYY MM DD

78. Did the donor submit a research sample to the NMDP/CIBMTR repository? **(Related donors only)**

☐ Yes – ***Go to question 79.***

☐ No – ***Go to question 80.***

79. Research sample donor ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

A series of collections should be considered a single product when they are all from the same donor and use the same collection method and technique (and mobilization, if applicable), even if the collections are performed on different days.

80. Specify number of products infused from this donor: ___ ___

81. Specify the number of these products intended to achieve hematopoietic engraftment: ___ ___

Questions 82.-83. are for autologous HCT recipients only. If other than autologous skip to question 84..

82. What agents were used to mobilize the autologous recipient for this HCT? *(check all that apply)*

☐ G-CSF (filgrastim, Neupogen)

☐ Pegylated G-CSF (pegfilgrastim, Neulasta)

☐ Plerixafor (Mozobil)

☐ Combined with chemotherapy

☐ Anti-CD20 (rituximab, Rituxan)

☐ Other agent**– *Go to question 83.***

83. Specify other agent: _____

To report more than one donor, copy questions 48.-83. **and complete for each donor.**

Clinical Status of Recipient Prior to the Preparative Regimen (Conditioning)

84. What scale was used to determine the recipient's functional status?

☐ Karnofsky *(recipient age ≥ 16 years)* – ***Go to question 85.***

☐ Lansky *(recipient age ≥ 1 year and < 16 years)* – ***Go to question 86.***

Performance score prior to the preparative regimen:

85. Karnofsky Scale *(recipient age ≥ 16 years)*

- ☐ 100 Normal; no complaints; no evidence of disease - ***Go to question 87.***
- ☐ 90 Able to carry on normal activity - ***Go to question 87.***
- ☐ 80 Normal activity with effort - ***Go to question 87.***
- ☐ 70 Cares for self; unable to carry on normal activity or to do active work - ***Go to question 87.***
- ☐ 60 Requires occasional assistance but is able to care for most needs - ***Go to question 87.***
- ☐ 50 Requires considerable assistance and frequent medical care - ***Go to question 87.***
- ☐ 40 Disabled; requires special care and assistance - ***Go to question 87.***
- ☐ 30 Severely disabled; hospitalization indicated, although death not imminent - ***Go to question 87.***
- ☐ 20 Very sick; hospitalization necessary - ***Go to question 87.***
- ☐ 10 Moribund; fatal process progressing rapidly - ***Go to question 87.***

86. Lansky Scale (recipient age ≥ 1 year and < 16 years)

- ☐ 100 Fully active
- ☐ 90 Minor restriction in physically strenuous play
- ☐ 80 Restricted in strenuous play, tires more easily, otherwise active
- ☐ 70 Both greater restrictions of, and less time spent in, active play
- ☐ 60 Ambulatory up to 50% of time, limited active play with assistance / supervision
- ☐ 50 Considerable assistance required for any active play; fully able to engage in quiet play
- ☐ 40 Able to initiate quiet activities
- ☐ 30 Needs considerable assistance for quiet activity
- ☐ 20 Limited to very passive activity initiated by others (e.g., TV)
- ☐ 10 Completely disabled, not even passive play

87. Recipient CMV-antibodies (IgG or Total)

- ☐ Reactive
- ☐ Non-reactive
- ☐ Indeterminate
- ☐ Not done

Comorbid Conditions

88. Has the patient been infected with COVID-19 (SARS-CoV-2) based on a positive test result at any time prior to the start of the preparative regimen / infusion?

- ☐ Yes – ***Go to question 89.***

OMB No: 0915-0310 Expiration Date: 10/31/2022

☐ No – ***Go to question 91.***

89. Did the patient require hospitalization for management of COVID-19 (SARS-CoV-2) infection?

☐ Yes

☐ No

90. Was mechanical ventilation given for COVID-19 (SARS-CoV-2) infection?

☐ Yes

☐ No

91. Is there a history of mechanical ventilation *(excluding COVID-19 (SARS-CoV-2))*?

☐ Yes

☐ No

92. Is there a history of invasive fungal infection?

☐ Yes

☐ No

93. Glomerular filtration rate (GFR) before start of preparative regimen **(pediatric only)**

☐ Known- ***Go to question 94.***

☐ Unknown- ***Go to question 95.***

94. Glomerular filtration rate (GFR): __ __ __ mL/min/1.73^2

95. Does the recipient have known complex congenital heart disease? *(corrected or uncorrected) (excluding simple ASD, VSD, or PDA repair) (pediatric only)*

☐ Yes

☐ No

96. Were there any co-existing diseases or organ impairment present according to the HCT comorbidity index (HCT-CI)? *(Source: Sorror, M. L. (2013). How I assess comorbidities before hematopoietic cell transplantation. Blood, 121(15), 2854-2863.)*

☐ Yes- ***Go to question 97.***

☐ No- ***Go to question 103.***

97. Specify co-existing diseases or organ impairment *(check all that apply)*

☐ Arrhythmia - **Any history of atrial fibrillation or flutter, sick sinus syndrome, or ventricular arrhythmias requiring treatment**

- ☐ Cardiac -**Any history of coronary artery disease (one or more vessel-coronary artery stenosis requiring medical treatment, stent, or bypass graft), congestive heart failure, myocardial infarction, OR ejection fraction ≤ 50% on the most recent test**
- ☐ Cerebrovascular disease **-Any history of transient ischemic attack, subarachnoid hemorrhage or cerebral thrombosis, embolism, or hemorrhage**
- ☐ Diabetes **-Requiring treatment with insulin or oral hypoglycemic drugs in the last 4 weeks but not diet alone**
- ☐ Heart valve disease **-At least a moderate to severe degree of valve stenosis or insufficiency as determined by Echo; prosthetic mitral or aortic valve; or symptomatic mitral valve prolapse**
- ☐ Hepatic, mild **- Bilirubin > upper limit of normal to 1.5 × upper limit of normal, or AST/ALT > upper limit of normal to 2.5 × upper limit of normal at the time of transplant OR any history of hepatitis B or hepatitis C infection**
- ☐ Hepatic, moderate/severe **-Liver cirrhosis, bilirubin > 1.5 × upper limit of normal, or AST/ALT > 2.5 × upper limit of normal**
- ☐ Infection **-Includes a documented infection, fever of unknown origin, or pulmonary nodules suspicious for fungal pneumonia or a positive PPD test requiring prophylaxis against tuberculosis. Patients must have started antimicrobial treatment before Day 0 with continuation of antimicrobial treatment after Day 0**
- ☐ Inflammatory bowel disease **-Any history of Crohn's disease or ulcerative colitis requiring treatment**
- ☐ Obesity **-Patients older than 18 years with a body mass index (BMI) > 35 kg/m2 prior to the start of conditioning or a BMI of the 95th percentile of higher for patients aged 18 years or younger**
- ☐ Peptic ulcer **-Any history of peptic (gastric or duodenal) ulcer confirmed by endoscopy or radiologic diagnosis requiring treatment**
- ☐ Psychiatric disturbance **-Presence of any mood (e.g., depression), anxiety, or other psychiatric disorder (e.g. bipolar disorder or schizophrenia) requiring continuous treatment in the last 4 weeks**
- ☐ Pulmonary, moderate **-Corrected diffusion capacity of carbon monoxide and/or FEV1 of 66-80% or dyspnea on slight activity attributed to pulmonary disease at transplant**
- ☐ Pulmonary, severe **-Corrected diffusion capacity of carbon monoxide and/or FEV1 of ≤ 65% or dyspnea at rest attributed to pulmonary disease or the need for intermittent or continuous oxygen during the 4 weeks prior to transplant**
- ☐ Renal, moderate / severe **-Serum creatinine > 2 mg/dL or > 177 µmol/L; on dialysis during the 4 weeks prior to transplant; OR prior renal transplantation *-go to question 98.***
- ☐ Rheumatologic **-Any history of a rheumatologic disease (e.g., systemic lupus erythematosis, rheumatoid arthritis, polymyositis, mixed connective tissue disease, or polymyalgia rheumatica, etc.) requiring treatment. (Do NOT include degenerative joint disease, osteoarthritis)**
- ☐ Prior malignancy-**Treated at any time point in the patient's past history, other than the primary disease for which this infusion is being performed *-go to question 99.***

98. Was the recipient on dialysis immediately prior to start of preparative regimen?

- ☐ Yes
- ☐ No
- ☐ Unknown

99. Specify prior malignancy *(check all that apply)*

- ☐ Breast cancer
- ☐ Central nervous system (CNS) malignancy *(e.g., glioblastoma, astrocytoma)*
- ☐ Gastrointestinal malignancy *(e.g., colon, rectum, stomach, pancreas, intestine, esophageal)*
- ☐ Genitourinary malignancy *(e.g., kidney, bladder, ovary, testicle, genitalia, uterus, cervix, prostate)*
- ☐ Leukemia *(includes acute or chronic leukemia)*
- ☐ Lung cancer
- ☐ Lymphoma *(includes Hodgkin & non-Hodgkin lymphoma)*
- ☐ MDS / MPN
- ☐ Melanoma
- ☐ Multiple myeloma / plasma cell disorder (PCD)
- ☐ Oropharyngeal cancer *(e.g., tongue, buccal mucosa)*
- ☐ Sarcoma
- ☐ Thyroid cancer
- ☐ Other skin malignancy *(basal cell, squamous)* ***- go to question 100.***
- ☐ Other hematologic malignancy ***-go to question 101.***
- ☐ Other solid tumor, prior ***-go to question 102.***

100. Specify other skin malignancy: *(prior)*
_____

101. Specify other hematologic malignancy: *(prior)*
_____

102. Specify other solid tumor: *(prior)* _____

Use results within 4 weeks prior to the start of the preparative regimen, report results from the test performed closest to the start date. Biomarkers according to the augmented HCT comorbidity index. (*Source: Biol Blood Marrow Transplant. 2015 Aug; 21(8): 1418–1424)*

103. Serum ferritin *(within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)*

- ☐ Known – ***Go to question 104.***
- ☐ Unknown – ***Go to question 107.***

104. ___ ___ ___ ___ ___ ng/mL (µg/L)

105. Date sample collected: ___ ___ ___ ___ — ___ ___ — ___ ___

YYYY MM DD

106. Upper limit of normal for your institution: ___ ___ ___ ___ ___

107. Serum albumin *(within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)*

☐ Known – ***Go to question 108.***

☐ Unknown – ***Go to question 110.***

108. ___ ___ • ___ ☐ g/dL

☐ g/L

109. Date sample collected: ___ ___ ___ ___ — ___ ___ — ___ ___

YYYY MM DD

110. Platelets *(within 4 weeks prior to the start of the preparative regimen, use result closest to the start date)*

☐ Known – ***Go to question 111.***

☐ Unknown – ***Go to question 113.***

111. ___ ___ ___ ___ ___ ___ ___ ☐ x 10^9/L (x 10^3/mm^3)

☐ x 10^6/L

112. Were platelets transfused ≤ 7 days before date of test?

☐ Yes

☐ No

☐ Unknown

113. Did the recipient have a prior solid organ transplant?

☐ Yes- ***Go to question 114.***

☐ No- ***Go to question 117.***

114. Specify organ:

☐ Bowel

☐ Heart

☐ Kidney(s)

☐ Liver

☐ Lung(s)

☐ Pancreas

OMB No: 0915-0310 Expiration Date: 10/31/2022

☐ Other organ- ***Go to question 115.***

115. Specify other organ: _____

116. Year of prior solid organ transplant: ___ ___ ___ ___
YYYY

Copy and complete questions 114.-116. for each prior solid organ transplant

Pre-HCT Preparative Regimen (Conditioning)

117. Height at initiation of pre-HCT preparative regimen: ___ ___ ___ ☐ inches
☐ centimeters

118. Actual weight at initiation of pre-HCT preparative regimen: ___ ___ ___ . ___ ☐ pounds
☐ kilograms

119. Was a pre-HCT preparative regimen prescribed?

☐ Yes – ***Go to question 120.***

☐ No – ***Go to question 141.***

120. Classify the recipient's prescribed preparative regimen **(Allogeneic HCTs only)**

☐ Myeloablative

☐ Non-myeloablative (NST)

☐ Reduced intensity (RIC)

121. Was irradiation planned as part of the pre-HCT preparative regimen?

☐ Yes – ***Go to question 122.***

☐ No – ***Go to question 127.***

122. What was the prescribed radiation field?

☐ Total body – ***Go to question 123.***

☐ Total body by intensity-modulated radiation therapy (IMRT) – ***Go to question 123.***

☐ Total lymphoid or nodal regions – ***Go to question 123.***

☐ Thoracoabdominal region – ***Go to question 123.***

123. Total prescribed dose: *(dose per fraction x total number of fractions)* ___ ___ ___ ___ . ___ ☐ Gy

OMB No: 0915-0310 Expiration Date: 10/31/2022

 cGy

124. Date started: ___ ___ ___ ___ — ___ ___ — ___ ___
YYYY MM DD

125. Was the radiation fractionated?

☐ Yes – ***Go to question 126.***

☐ No – ***Go to question 127.***

126. Total number of fractions: ___ ___

Indicate the total prescribed cumulative dose for the preparative regimen

127. Drug *(drop down list)*

- ☐ Bendamustine
- ☐ Busulfan
- ☐ Carboplatin
- ☐ Carmustine (BCNU)
- ☐ CCNU (Lomustine)
- ☐ Clofarabine (Clolar)
- ☐ Cyclophosphamide (Cytoxan)
- ☐ Cytarabine (Ara-C)
- ☐ Etoposide (VP-16, VePesid)
- ☐ Fludarabine
- ☐ Gemcitabine
- ☐ Ibritumomab tiuxetan (Zevalin)
- ☐ Ifosfamide
- ☐ Melphalan (L-Pam)
- ☐ Methylprednisolone (Solu-Medrol)
- ☐ Pentostatin
- ☐ Propylene glycol-free melphalan (Evomela)
- ☐ Rituximab (Rituxan)
- ☐ Thiotepa
- ☐ Tositumomab (Bexxar)
- ☐ Treosulfan
- ☐ Other drug ***-go to question 128.***

128. Specify other drug: _____

129. Total prescribed dose: __ __ __ __ __. __ □ mg/m^2
□ mg/kg
□ AUC (mg x h/L)
□ AUC (µmol x min/L)
□CSS (ng/mL)

130. Date started: ___ ___ ___ ___ — ___ ___ — ___ ___
YYYY MM DD

131. Specify administration *(busulfan only)*
- ☐ Oral
- ☐ IV
- ☐ Both

Copy and complete question 127.-131. to report each drug given for the preparative regimen

Additional Drugs Given in the Peri-Transplant Period

132. ALG, ALS, ATG, ATS
- ☐ Yes – ***Go to question 133.***
- ☐ No – ***Go to question 136.***

133. Total prescribed dose: ___ ___ ___ ___ ___ mg/kg

134. Specify source
- ☐ ATGAM (horse) – ***Go to question 136.***
- ☐ ATG – Fresenius (rabbit) – ***Go to question 136.***
- ☐ Thymoglobulin (rabbit) – ***Go to question 136.***
- ☐ Other – ***Go to question 135.***

135. Specify other source: _____

136. Alemtuzumab (Campath)
- ☐ Yes – ***Go to question 137.***
- ☐ No – ***Go to question 138.***

137. Total prescribed dose: __ __ __ __ . __ □ mg/m2

OMB No: 0915-0310 Expiration Date: 10/31/2022

□ mg/kg

□mg

138. Defibrotide

☐ Yes

☐ No

139. KGF

☐ Yes

☐ No

140. Ursodiol

☐ Yes

☐ No

GVHD Prophylaxis

This section is to be completed for allogeneic HCTs only; autologous HCTs continue with question 144..

141. Was GVHD prophylaxis planned?

☐ Yes - ***Go to question 142.***

☐ No - ***Go to question 144.***

142. Specify drugs / intervention *(check all that apply)*

- ☐ Abatacept
- ☐ Anti CD 25 (Zenapax, Daclizumab, AntiTAC)
- ☐ Bortezomib
- ☐ CD34 enriched (CD34+ selection)
- ☐ Corticosteroids (systemic)
- ☐ Cyclophosphamide (Cytoxan)
- ☐ Cyclosporine (CSA, Neoral, Sandimmune)
- ☐ Extra-corporeal photopheresis (ECP)
- ☐ Ex-vivo T-cell depletion
- ☐ Filgotinib

OMB No: 0915-0310 Expiration Date: 10/31/2022

- ☐ Maraviroc
- ☐ Methotrexate (MTX) (Amethopterin)
- ☐ Mycophenolate mofetil (MMF) (CellCept)
- ☐ Ruxolotinib
- ☐ Sirolimus (Rapamycin, Rapamune)
- ☐ Tacrolimus (FK 506)
- ☐ Tocilizumab
- ☐ Blinded randomized trial
- ☐ Other agent-***go to question 143.***

143. Specify other agent: _____ *(do not report ATG, campath)*

Post-HCT Disease Therapy Planned as of Day 0

144. Is additional post-HCT therapy planned?

- ☐ Yes - ***Go to question 145.***
- ☐ No - ***Go to First Name***

Questions 145.-146. are optional for non-U.S. centers

145. Specify post-HCT therapy planned *(check all that apply)*

- ☐ Azacytidine (Vidaza)
- ☐ Blinatumomab
- ☐ Bortezomib (Velcade)
- ☐ Bosutinib
- ☐ Brentuximab
- ☐ Carfilzomib
- ☐ Cellular therapy *(e.g. DCI, DLI)*
- ☐ Crenolanib
- ☐ Daratumumab
- ☐ Dasatinib
- ☐ Decitabine
- ☐ Elotuzumab
- ☐ Enasidenib
- ☐ Gilteritinib
- ☐ Ibrutinib

OMB No: 0915-0310 Expiration Date: 10/31/2022

- ☐ Imatinib mesylate (Gleevec, Glivec)
- ☐ Intrathecal therapy *(chemotherapy)*
- ☐ Ivosidenib
- ☐ Ixazomib
- ☐ Lenalidomide (Revlimid)
- ☐ Lestaurtinib
- ☐ Local radiotherapy
- ☐ Midostaurin
- ☐ Nilotinib
- ☐ Obinutuzumab
- ☐ Pacritinib
- ☐ Ponatinib
- ☐ Quizartinib
- ☐ Rituximab (Rituxan, MabThera)
- ☐ Sorafenib
- ☐ Sunitinib
- ☐ Thalidomide (Thalomid)
- ☐ Other therapy- ***Go to question 146.***
- ☐ Unknown

146. Specify other therapy: _____

Prior Exposure: Potential Study Eligibility

Selecting any option(s) below may generate an additional supplemental form.

147. Specify if the recipient received any of the following *(at any time prior to HCT / infusion) (check all that apply)*

- ☐ Blinatumomab (Blincyto)
- ☐ Gemtuzumab ozogamicin (Mylotarg)
- ☐ Inotuzumab ozogamicin (Besponsa)
- ☐ Adienne Tepadina®
- ☐ Mogamulizumab (Poteligeo)
- ☐ None of the above

OMB No: 0915-0310 Expiration Date: 10/31/2022

CIBMTR Center Number: ___ ___ ___ ___ ___ CIBMTR Research ID: ___ ___ ___ ___ ___ ___ ___ ___ ___ ___

First Name: _____

Last Name: _____

E-mail address:

Date: ___ ___ ___ ___ — ___ ___ — ___ ___

YYYY MM DD